CROSSJECT overview

Press Release CROSSJECT provides updates on the EUA filing of ZEPIZURE® CROSSJECT and its EUROFINS CDMO partner successfully completed the aseptic filling of all ZEPIZURE® registration batches and anticipate the delivery of the last manufacturing data needed for U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) submission in June 2025. CROSSJECT started the final regulatory activities for the ZEPIZURE® dossier submission under EUA. CROSSJECT began manufacturing EUA...

Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025. Recruitment of Tony Tipton as Chief Operating Officer USA. Visibility gained on pipeline programs developed in collaboration with Eton Pharmaceuticals, Inc (Eton). Cash position increasing significantly to 7 million euros as of December 31, 2024. Dijon, France, March 27, 2025 (07.30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ) a...

Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON’s net sales. ETON confirmed its commitment to finalize the development and...

Press Release CROSSJECT achieves key ZEPIZURE ® manufacturing batch stability milestones Satisfactory 6-month room temperature stability results for the Registration Batch of ZEPIZURE®; CDMO Partner EUROFINS in the process of producing additional validation batches as part of regulatory application; Manufacturing progress supports timelines toward filing of Emergency Use Authorization application by BARDA. Dijon, France March 18, 2025 CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty...

Dijon, FRANCE, February 12, 2025 – 0730 (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces that, as of February 17, its Executive Board will be made up of Patrick Alexandre, Chairman, and Isabelle Liebschutz, Quality and Regulatory Affairs Director and the Company’s qualified person....

Press Release Dijon, FRANCE, February 6, 2025 –0730h (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces, in accordance with the agreement entered into with Heights in December 2024, the completion of the amendments of the terms and conditions of the bonds issued to an entity affiliated to...

Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France) Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company preparing to commercialize its epilepsy rescue therapy ZEPIZURE®, has successfully concluded a surveillance audit of its manufacturing sites, delivering new evidence its supply chain is ready to move ZEPIZURE®...

Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025 Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafter Crossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that year Dijon, France, October 22 2024 (07:30 CET) - Crossject...